Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
Active, not recruiting · NCT04708041 · Registry updated 2025-04-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) | DNA Virus Infections, Disease Attributes, Genital Diseases, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, Urogenital Diseases, human papilloma virus infection, infectious disease, sexually transmitted disease, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 3 | 2025-04-20 | NCT04708041 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
30 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.